New cases of cancer are expected to reach 3.4 million in 2040 in Europe
Projections by the European Commission – Joint Research Centre from Ispra, Italy, estimate a 21.4% increase in cancer cases in 20 years’ time
Projections by the European Commission – Joint Research Centre from Ispra, Italy, estimate a 21.4% increase in cancer cases in 20 years’ time
Malignant pleural mesothelioma is a rare and fatal disease with very little improvement in survival in recent years, mirroring very limited therapeutic advances. After a long-awaited time, improvement in patient survival was achieved with the introduction of nivolumab plus ipilimumab in the first-line setting, as demonstrated in the CheckMate 743 trial.
Findings from several studies highlight the increasing utility of this approach to identify druggable genetic alterations
Most, but not all, patients on chemotherapy or immunotherapy for solid tumours had an adequate immune response after two doses of mRNA-1273 vaccination, with no new safety concerns
In the NeoTRIPaPDL1 study, combining information from biomarker analysis at baseline and during treatment was informative on clinical benefit
Results show it may help to define more homogeneous subgroups of patients with grade II–III glioma for more timely and effective cancer care
A Japanese study reports discrepancies among centres, highlighting the need for better strategies to improve the quality of treatment recommendations
Rare tumours have been neglected for decades, with lack of funding, lack of research and lack of visibility. It is encouraging to see how this is changing and how research in rare tumours is not only taking place, but also being highlighted in Presidential Symposium 3 at this year’s ESMO Congress.
An exploratory analysis from the IMpower010 trial adds support to the use of post-chemotherapy adjuvant immunotherapy for selected early stage non-small-cell lung cancer
Data from SECOMBIT provide useful insights to the optimal sequence of immune checkpoint inhibitor therapy and targeted treatment combinations for patients with BRAF-mutated, advanced melanoma
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.